Funding Announcements

Filter

Filter & sort

Keyword

Tag

Round

Sort by

Clear

The latest funding rounds from the UK tech ecosystem. Updated 31 July 2026.

Seed
£1.7M

The Edinburgh based smart home security start up secured £1.7m from angel investors and a construction firm.

"It became very clear from my discussions with investors over recent months that they like the space Boundary is operating in. We have worked hard to get to grips with the stringent regulatory framework that exists around the police response intruder alarm market and this is clearly a key strength of the Boundary model."
— Robin Knox, CEO
Series A
£2.7M

The investment from Maven VCTs and the Scottish Investment Bank will support international expansion and sales growth.

"We are delighted to be leading the investment in Quorum Cyber which is trusted by a diverse range of clients and which we believe is ideally positioned to capitalise on the significant growth within the cyber security space. The senior team at Quorum have built a business with an enviable reputation and culture and we look forward to working with them over the coming years to scale the business."
— David Milroy, Partner
Seed
$0

Alpha Sigma Capital led the seed investment to help Quant Network expand its blockchain interoperability technology into new markets.

"We just recognized that Quant is doing what Ripple promised. Quant and SIA Europe successfully tested cross-blockchain interoperability between multiple Distributed Ledger Technology (DLT) protocols on SIA’s inter-bank network, SIAnet. SIA is the backbone for financial institutions, central banks, corporates, and the public sector to process their transactions. It was clear that Quant’s operating system provides the layer for blockchain interoperability in the financial services sector."
— Enzo Villani, Managing Partner
Series A
£5.1M

The financing will support clinical trials, product development and team expansion as the business pursues international regulatory approvals.

"Our work in the US and the success of the trials we have run to date have demonstrated the potential of our technology and encouraged us to pursue other applications. With this financing and the backing of our investors we can accelerate our mission of delivering effective and non-invasive solutions for some of the most common and debilitating medical conditions."
— Jason McKeown, CEO